ACEA 1328

Drug Profile

ACEA 1328

Latest Information Update: 21 Jul 1999

Price : $50

At a glance

  • Originator Purdue Pharma
  • Class Analgesics; Drug withdrawal therapies
  • Mechanism of Action Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 21 Jul 1999 Discontinued-Preclinical for Pain in USA (Unknown route)
  • 04 Sep 1998 A study has been added to the pharmacodynamics section
  • 04 Nov 1996 Preclinical development for Pain in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top